Versigent (NYSE:VGNT) Given Consensus Recommendation of “Buy” by Analysts

Versigent (NYSE:VGNT) has received an average recommendation of “Buy” from the thirteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $49.6667.

A number of analysts have recently weighed in on the stock. Zacks Research upgraded shares of Versigent from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 2nd. TD Cowen increased their price target on shares of Versigent from $47.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley started coverage on Versigent in a research report on Friday, May 8th. They issued an “overweight” rating and a $51.00 price target for the company. The Goldman Sachs Group started coverage on Versigent in a research note on Monday, July 20th. They set a “buy” rating and a $48.00 price objective on the stock. Finally, UBS Group decreased their price objective on Versigent from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, July 9th.

Versigent Trading Down 0.1%

Versigent stock opened at $41.62 on Monday. The company’s fifty day simple moving average is $43.27. Versigent has a 52-week low of $26.34 and a 52-week high of $50.88.